EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial

Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, Yanqiu Zhao, Ruifen Tian, Dianming Li, Ruiling Ning, Qingshan Li, Guowu Wu und 6 weitere

Cancer Communications · 01.01.2026 · 46

DOI: 10.34133/cancomm.0068 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Communications, online erschienen am 10.11.2026. Verfasst von Ying Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, Jilin, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crizotinib, Lung Neoplasms, Anaplastic Lymphoma Kinase. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Xuanzhu Biopharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dirozalkib is a highly selective anaplastic lymphoma kinase ( ALK ) inhibitor with intracranial antitumor activity against crizotinib-resistant mutations. This phase III trial evaluated dirozalkib versus crizotinib in patients with ALK inhibitor-naïve, ALK -positive, advanced non-small-cell lung cancer (NSCLC).

Methods

In this multicenter, randomized, open-label DIAMOND-2 trial, adult patients with ALK inhibitor-naïve, ALK -positive, advanced NSCLC who either had received no prior systemic therapy or had experienced disease progression or intolerance after one prior chemotherapy regimen were randomly assigned 1:1 to dirozalkib (500 mg once daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival (PFS).

Results

Between 2022 January 24 and 2023 April 30, 275 patients were randomly assigned to receive dirozalkib ( n = 137) or crizotinib ( n = 138). As of 2025 May 31, the median follow-up durations were 32.8 and 31.6 months, respectively. Median investigator-assessed PFS was 29.5 (95% confidence interval [CI] = 20.3 to not reached) months with dirozalkib versus 12.9 (95% CI = 11.1 to 17.6) months with crizotinib (hazard ratio [HR] = 0.47, 95% CI = 0.34 to 0.66; P < 0.001). Blinded-independent-central-review-assessed PFS was also significantly prolonged with dirozalkib (median PFS, 27.5 versus 12.9 months; HR = 0.54, 95% CI = 0.39 to 0.74; P < 0.001). Grade ≥3 treatment-emergent adverse events (TEAEs) were less frequent with dirozalkib than with crizotinib (60.6% versus 72.5%), and TEAEs led to treatment discontinuation in 2.2% and 7.2% of patients, respectively.

Conclusions

Dirozalkib significantly improved PFS versus crizotinib, with a manageable safety profile, supporting its use as a first-line therapy for ALK -positive advanced NSCLC.

Trial registration

This trial was registered at ClinicalTrials.gov on 2022 January 24 (NCT05204628).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCrizotinibLung NeoplasmsAnaplastic Lymphoma KinaseProtein Kinase InhibitorsHumansFemaleMiddle AgedMaleAgedAdultAged, 80 and over

Substanzen

CrizotinibAnaplastic Lymphoma KinaseProtein Kinase InhibitorsALK protein, human

Autor:innen und Institutionen

  • Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, Jilin, P. R. China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
  • Department of Thoracic Medical Oncology, The Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China.
  • Department of Thoracic Medical Oncology, Hunan Provincial Cancer Hospital, Changsha, Hunan, P. R. China.
  • Department of Medical Oncology, Yunnan Provincial Cancer Hospital, Kunming, Yunnan, P. R. China.
  • Department of Respiratory and Critical Care Medicine, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong, P. R. China.

Förderung

  • Xuanzhu Biopharmaceutical Co., Ltd.

Zitieren

APA

Liu, Y., Meng, X., Yu, Y., Chen, J., Yang, R., Liu, L., Zhao, Y., Tian, R., Li, D., Ning, R., Li, Q., Wu, G., Wang, L., Duan, X., Guo, X., Hu, Y., Liu, W., & Liu, H. (2026). Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0068

Vancouver

Liu Y, Meng X, Yu Y, Chen J, Yang R, Liu L, et al. Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial. Cancer Communications. 2026;46. doi:10.34133/cancomm.0068

BibTeX
@article{Liu2026,
  author = {Liu, Ying and Meng, Xiangjiao and Yu, Yan and Chen, Jianhua and Yang, Runxiang and Liu, Laiyu and Zhao, Yanqiu and Tian, Ruifen and Li, Dianming and Ning, Ruiling and Li, Qingshan and Wu, Guowu and Wang, Li and Duan, Xianghui and Guo, Xuejie and Hu, Yan and Liu, Weili and Liu, Haifeng},
  title = {Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial},
  journal = {Cancer Communications},
  year = {2026},
  volume = {46},
  doi = {10.34133/cancomm.0068}
}
Kostenlos starten →